Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIB, Randomized, Double blinded, Placebo controlled, Parallel group Study to Evaluate the Efficacy and Safety of MEDI6570 inParticipants with a Prior Myocardial Infarction, Persistent Inflammation, and Elevated N terminal Prohormone Brain Natriuretic Peptide

Next Previous
X
Search
Trial Profile

A Phase IIB, Randomized, Double blinded, Placebo controlled, Parallel group Study to Evaluate the Efficacy and Safety of MEDI6570 inParticipants with a Prior Myocardial Infarction, Persistent Inflammation, and Elevated N terminal Prohormone Brain Natriuretic Peptide

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MEDI-6570 (Primary)
  • Indications Atherosclerosis; Postmyocardial infarction
  • Focus Proof of concept; Therapeutic Use
  • Acronyms GOLDILOX; GOLDILOX-TIMI 69
  • Sponsors AstraZeneca; AstraZeneca AB

    • Most Recent Events

    • 27 Nov 2023 Status changed from active, no longer recruiting to completed.
    • 28 Jul 2023 According to an AstraZeneca media release, result data of this study will be anticipated in H1 2024.
    • 16 Mar 2023 Planned End Date changed from 14 Feb 2024 to 20 Nov 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top